adebrelimab + albumin paclitaxel

A combination therapy consisting of **adebrelimab**, a monoclonal antibody immunotherapy, and **albumin-bound paclitaxel** (Abraxane, also known as nab-paclitaxel), a solvent-free, nanoparticle formulation of the chemotherapeutic agent paclitaxel. - **Adebrelimab** is a PD-L1 (programmed death-ligand 1) inhibitor, which blocks the interaction between PD-L1 and its receptor PD-1, thereby enhancing the immune system's ability to attack tumor cells. - **Albumin-bound paclitaxel** is a nanotechnology-enabled formulation in which paclitaxel is bound to albumin nanoparticles, facilitating its delivery to tumors via endogenous albumin transport pathways, including receptor-mediated transcytosis and improved permeability and retention (EPR) effect[1][3][4]. This formulation avoids the toxic solvents needed for conventional paclitaxel and enables higher drug delivery to tumor tissues, leading to increased efficacy and reduced hypersensitivity reactions compared to solvent-based paclitaxel[3][4][1]. This combination is investigated in oncology, leveraging the immunomodulatory effects of adebrelimab and the cytotoxic effects of albumin-bound paclitaxel. Primary indications include various **solid tumors**, often in advanced or metastatic settings.

Brand names

Abraxane

Other names

nab-paclitaxelpaclitaxel protein-bound particlesABI-007ABI007ABI 007